Merck: to present new data at IDWeek 2024
(CercleFinance.com) - Merck announces its participation in IDWeek 2024, where it will present new data on its vaccines and treatments for infectious diseases.
Results include a detailed presentation of the Phase 2b/3 trial of clesrovimab, an investigational monoclonal antibody against respiratory syncytial virus (RSV) in infants.
Data on the CAPVAXIVE vaccine against pneumococcal infections in at-risk adults and a weekly treatment against HIV-1 will also be presented.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Results include a detailed presentation of the Phase 2b/3 trial of clesrovimab, an investigational monoclonal antibody against respiratory syncytial virus (RSV) in infants.
Data on the CAPVAXIVE vaccine against pneumococcal infections in at-risk adults and a weekly treatment against HIV-1 will also be presented.
Copyright (c) 2024 CercleFinance.com. All rights reserved.